"Chinese Expert Consensus on the Use of Biologics in Patients with Chronic Rhinosinusitis (2022, Zhuhai)"
作者全名："Hong, Hai-yu; Chen, Teng-yu; Yang, Qin-tai; Sun, Yue-qi; Chen, Feng-hong; Lou, Hong-fei; Wang, Hong-tian; Yu, Rui-li; An, Yun-fang; Liu, Feng; Wang, Tian-sheng; Lu, Mei-ping; Qiu, Qian-hui; Wang, Xiang-dong; Chen, Jian-jun; Meng, Cui-da; Xie, Zhi-hai; Meng, Juan; Zeng, Ming; Xu, Cheng-li; Wang, Ying; Yang, Yu-cheng; Zhang, Wei-tian; Tang, Jun; Yang, Yan-li; Xu, Rui; Yu, Guo-dong; Shi, Zhao-hui; Wei, Xin; Ye, Hui-ping; Sun, Ya-nan; Yu, Shao-qing; Zhang, Tian-hong; Yong, Jun; Hang, Wei; Xu, Yuan-teng; Xu, Yu; Tan, Guo-lin; Sun, Na; Yang, Gui; Li, You-jin; Ye, Jing; Zuo, Ke-jun; Zhang, Li-qiang; Wang, Xue-yan; Yang, An-ni; Xu, Ying-xiang; Liao, Wei; Fan, Yun-ping; Li, Hua-bin"
作者地址："[Hong, Hai-yu; Chen, Teng-yu; Yang, An-ni; Xu, Ying-xiang; Liao, Wei] Sun Yat Sen Univ, Affiliated Hosp 5, Allergy Ctr, Dept Otolaryngol, Zhuhai, Peoples R China; [Yang, Qin-tai] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Otolaryngol Head & Neck Surg, Guangzhou, Peoples R China; [Yang, Qin-tai] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Allergy, Guangzhou, Peoples R China; [Sun, Yue-qi; Fan, Yun-ping] Sun Yat Sen Univ, Affiliated Hosp 7, Dept Otolaryngol, Shenzhen, Peoples R China; [Chen, Feng-hong; Xu, Rui; Zuo, Ke-jun] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Otolaryngol, Guangzhou, Peoples R China; [Lou, Hong-fei; Li, Hua-bin] Fudan Univ, Eye & ENT Hosp, Dept Otolaryngol, Shanghai, Peoples R China; [Wang, Hong-tian; Yu, Rui-li; Wang, Xue-yan] Capital Med Univ, Beijing Shijitan Hosp, Dept Allergy, Beijing, Peoples R China; [Wang, Hong-tian; Yu, Rui-li; Wang, Xue-yan] Capital Med Univ, Beijing Shijitan Hosp, Ctr Allergy, Beijing, Peoples R China; [An, Yun-fang] Shanxi Med Univ, Hosp 2, Dept Otolaryngol, Taiyuan, Peoples R China; [Liu, Feng; Meng, Juan] Sichuan Univ, West China Hosp, Dept Otolaryngol Head & Neck Surg, Chengdu, Peoples R China; [Wang, Tian-sheng; Tan, Guo-lin] Cent South Univ, Xiangya Hosp 3, Dept Otolaryngol Head & Neck Surg, Changsha, Peoples R China; [Lu, Mei-ping] Nanjing Med Univ, Affiliated Hosp 1, Dept Otolaryngol, Nanjing, Peoples R China; [Qiu, Qian-hui] Guangdong Prov Peoples Hosp, Dept Otolaryngol Head & Neck Surg, Guangzhou, Peoples R China; [Wang, Xiang-dong] Capital Med Univ, Dept Otolaryngol Head & Neck Surg, Beijing Tongren Hosp, Beijing, Peoples R China; [Chen, Jian-jun] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Otolaryngol, Wuhan, Peoples R China; [Meng, Cui-da] Jilin Univ, Dept Otolaryngol Head & Neck Surg, China Japan Friendship Hosp, Changchun, Peoples R China; [Xie, Zhi-hai] Cent South Univ, Dept Otolaryngol Head & Neck Surg, Xiangya Hosp, Changsha, Peoples R China; [Zeng, Ming] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Otolaryngol Head & Neck Surg, Wuhan, Peoples R China; [Xu, Cheng-li] Guangxi Med Univ, Affiliated Hosp 2, Dept Otolaryngol Head & Neck Surg, Nanning, Peoples R China; [Wang, Ying] Zhengzhou Univ, Hosp 1, Dept Rhinol, Zhengzhou, Peoples R China; [Yang, Yu-cheng] Chongqing Med Univ, Affiliated Hosp 1, Dept Otolaryngol Head & Neck Surg, Chongqing, Peoples R China; [Zhang, Wei-tian] Shanghai Jiao Tong Univ, Peoples Hosp 6, Dept Otolaryngol Head & Neck Surg, Shanghai, Peoples R China; [Tang, Jun] Sun Yat Sen Univ, Peoples Hosp 1, Dept Rhinol, Foshan, Peoples R China; [Yang, Yan-li] Kunming Med Univ, Affiliated Hosp 1, Dept Otolaryngol 1, Kunming, Peoples R China; [Yu, Guo-dong] Guizhou Med Univ, Affiliated Hosp, Dept Otolaryngol, Guiyang, Peoples R China; [Shi, Zhao-hui] ENT Hosp Shenzhen Longgang Dist, Dept Otolaryngol, Shenzhen, Peoples R China; [Wei, Xin] Hainan Peoples Hosp, Dept Otolaryngol Head & Neck Surg, Haikou, Peoples R China; [Ye, Hui-ping] Guizhou Prov Hosp, Dept Otolaryngol, Guiyang, Peoples R China; [Sun, Ya-nan] Harbin Med Univ, Affiliated Hosp 2, Dept Otolaryngol Head & Neck Surg, Harbin, Peoples R China; [Yu, Shao-qing] Tongji Univ, Dept Otolaryngol Head & Neck Surg, Tongji Hosp, Shanghai, Peoples R China; [Zhang, Tian-hong] Harbin Med Univ, Affiliated Hosp 1, Dept Otolaryngol Head & Neck Surg, Harbin, Peoples R China; [Yong, Jun] Xinjiang Med Univ, Affiliated Hosp 1, Dept Otolaryngol, Urumqi, Peoples R China; [Hang, Wei] Huanhu Hosp Tianjin City, Dept Otolaryngol Head & Neck Surg, Tianjin, Peoples R China; [Xu, Yuan-teng] Fujian Med Univ, Affiliated Hosp 1, Dept Otolaryngol, Fuzhou, Peoples R China; [Xu, Yu] Wuhan Univ, Renmin Hosp, Dept Otolaryngol Head & Neck Surg, Wuhan, Peoples R China; [Sun, Na] Fudan Univ, Huadong Hosp, Dept Otolaryngol, Shanghai, Peoples R China; [Yang, Gui] Cent Hosp Shenzhen Longgang Dist, Dept Otolaryngol, Shenzhen, Peoples R China; [Li, You-jin] Shanghai Jiao Tong Univ, Dept Otolaryngol, Shanghai Childrens Med Ctr, Shanghai, Peoples R China; [Ye, Jing] Nanchang Univ, Hosp Affiliated 1, Dept Otolaryngol Head & Neck Surg, Nanchang, Peoples R China; [Zhang, Li-qiang] Shandong Univ, Qilu Hosp, Dept Otolaryngol, Jinan, Peoples R China"
通信作者："Hong, HY (通讯作者)，Sun Yat Sen Univ, Affiliated Hosp 5, Allergy Ctr, Dept Otolaryngol, Zhuhai, Peoples R China.; Fan, YP (通讯作者)，Sun Yat Sen Univ, Affiliated Hosp 7, Dept Otolaryngol, Shenzhen, Peoples R China.; Li, HB (通讯作者)，Fudan Univ, Eye & ENT Hosp, Dept Otolaryngol, Shanghai, Peoples R China."
来源：ORL-JOURNAL FOR OTO-RHINO-LARYNGOLOGY HEAD AND NECK SURGERY
ESI学科分类：CLINICAL MEDICINE
WOS号：WOS:000964170000001
JCR分区：Q2
影响因子：1.5
年份：2023
卷号：
期号：
开始页：
结束页：
文献类型：Review; Early Access
关键词：Rhinosinusitis; Dupilumab; Omalizumab; Mepolizumab; Biologics
摘要："Background: Chronic rhinosinusitis (CRS) is a common inflammatory disease in otolaryngology, mainly manifested as nasal congestion, nasal discharge, facial pain/pressure, and smell disorder. CRS with nasal polyps (CRSwNP), an important phenotype of CRS, has a high recurrence rate even after receiving corticosteroids and/or functional endoscopic sinus surgery. In recent years, clinicians have focused on the application of biological agents in CRSwNP. However, it has not reached a consensus on the timing and selection of biologics for the treatment of CRS so far. Summary: We reviewed the previous studies of biologics in CRS and summarized the indications, contraindications, efficacy assessment, prognosis, and adverse effects of biologics. Also, we evaluated the treatment response and adverse reactions of dupilumab, omalizumab, and mepolizumab in the management of CRS and made recommendations. Key Messages: Dupilumab, omalizumab, and mepolizumab have been approved for the treatment of CRSwNP by the US Food and Drug Administration. Type 2 and eosinophilic inflammation, need for systemic steroids or contraindication to systemic steroids, significantly impaired quality of life, anosmia, and comorbid asthma are required for the use of biologics. Based on current evidence, dupilumab has the prominent advantage in improving quality of life and reducing the risk of comorbid asthma in CRSwNP among the approved monoclonal antibodies. Most patients tolerate biological agents well in general with few major or severe adverse effects. Biologics have provided more options for severe uncontrolled CRSwNP patients or patients who refuse to have surgery. In the future, more novel biologics will be assessed in high-quality clinical trials and applied clinically."
基金机构："National Natural Science Foundation of China [82071018, 81670901, 81371074, 82260219, 82101201, 81970864, 81870706]; National Natural Science Foundation for Distinguished Young Scholars of China [81725004]; Natural Science Foundation of Guangdong Province, China [2022A1515012617]; Zhuhai Science and Technology Planning Project [ZH22036201210047PWC]; Program of Shanghai Academic/Technology Research Leader [19XD4010000]; Major Project of Shanghai Otolaryngology Clinical Center [20MC920200]"
基金资助正文："This study was supported by the National Natural Science Foundation of China (Grant No. 82071018; 81670901; 81371074; 82260219; 82101201; 81970864; 81870706), National Natural Science Foundation for Distinguished Young Scholars of China (Grant No. 81725004), Natural Science Foundation of Guangdong Province, China (Grant No. 2022A1515012617), Zhuhai Science and Technology Planning Project (Grant No. ZH22036201210047PWC), Program of Shanghai Academic/Technology Research Leader (Grant No. 19XD4010000), and Major Project of Shanghai Otolaryngology Clinical Center (Grant No. 20MC920200)."
